Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : Pfe source : Www.biospace.com save search
Pfizer Invites Shareholders to Attend Virtual-Only 2024 Annual Meeting of Shareholders on April 25
Published: 2024-04-11 (Crawled : 20:00) - biospace.com/
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: 0.11%
H: 0.38%
C: -0.04%
meeting
Pfizer Announces Positive Top-Line Results from Phase 3 Study of ABRYSVO® in Adults Aged 18 to 59 at Increased Risk for RSV Disease
Published: 2024-04-09 (Crawled : 12:00) - biospace.com/
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: 0.73%
H: 2.49%
C: 0.11%
abrysvo disease positive risk for rsv results study
ViiV Healthcare announces U.S. FDA approval of Dovato (dolutegravir/lamivudine) for adolescents living with HIV
Published: 2024-04-08 (Crawled : 13:30) - biospace.com/
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: -0.39%
H: 0.0%
C: 0.0%
fda approval for hiv living
European Commission Approves Pfizer’s PREVENAR 20® to Help Protect Infants and Children Against Pneumococcal Disease
Published: 2024-03-13 (Crawled : 11:00) - biospace.com/
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: 1.0%
H: 1.41%
C: -0.25%
disease pneumococcal children
Pfizer Announces Positive Overall Survival in Phase 3 Trial of ADCETRIS® Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Published: 2024-03-12 (Crawled : 12:30) - biospace.com/
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: -0.21%
H: 0.11%
C: -1.06%
adcetris positive trial
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference - March 5, 2024
Published: 2024-03-05 (Crawled : 16:00) - biospace.com/
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: -0.08%
H: 2.13%
C: 0.81%
conference
ViiV Healthcare presents phase I clinical trial findings of a cabotegravir long-acting injectable investigational formulation allowing at least four months between doses
Published: 2024-03-04 (Crawled : 21:00) - biospace.com/
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: -1.09%
H: 0.61%
C: -1.56%
trial
Pfizer Announces Positive Top-Line Data for Full Season Two Efficacy of ABRYSVO® for RSV in Older Adults
Published: 2024-02-29 (Crawled : 16:00) - biospace.com/
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: 0.11%
H: 0.44%
C: -1.88%
abrysvo positive rsv
New Drug Study Shows Improving Sleep Quality Can Relieve Fibromyalgia Pain
Published: 2024-02-26 (Crawled : 00:00) - biospace.com/
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: -0.32%
H: 0.0%
C: -1.77%
TNXP | $0.1549 -2.82% -2.91% 1.4M
|
Health Technology
|
| O: 4.32%
H: 7.17%
C: 2.5%
drug fibromyalgia study
European Commission Approves Pfizer’s VELSIPITY® for Patients with Moderately to Severely Active Ulcerative Colitis
Published: 2024-02-19 (Crawled : 17:00) - biospace.com/
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
| Email alert
Add to watchlist
velsipity active
BlossomHill Therapeutics Chief Executive Officer, Jingrong Jean Cui, Ph.D., Elected to the National Academy of Engineering
Published: 2024-02-14 (Crawled : 14:00) - biospace.com/
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: 0.15%
H: 0.59%
C: 0.37%
therapeutics
Carrick Therapeutics Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Samuraciclib in Combination with Vepdegestrant in Patients with Advanced Breast Cancer
Published: 2024-02-14 (Crawled : 14:00) - biospace.com/
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: 0.15%
H: 0.59%
C: 0.37%
ARVN | $34.3 2.54% 2.48% 800K
|
Health Technology
|
| O: -1.09%
H: 5.61%
C: 4.49%
first breast cancer trial therapeutics advanced
Pfizer Reports Full-Year 2023 Results and Reaffirms Full-Year 2024 Financial Guidance
Published: 2024-01-30 (Crawled : 12:30) - biospace.com/
GNMSF | $281.02 3.83% 210
|
Health Technology
|
| O: 2.14%
H: 1.03%
C: -0.89%
ALPMF | $9.594 43.47% 2.2K
|
Health Technology
|
| O: 1.76%
H: 0.0%
C: 0.0%
ALPMY | $9.46 -1.11% 500K
|
Manufacturing
|
| O: -3.53%
H: 3.49%
C: 3.4%
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: 1.49%
H: 1.72%
C: -3.12%
GMAB | $28.32 -0.74% -0.74% 240K
|
Health Technology
|
| O: 0.42%
H: 0.04%
C: -0.99%
ARVN | $34.3 2.54% 2.48% 800K
|
Health Technology
|
| O: -0.46%
H: 0.79%
C: 0.28%
financial results
Enthera Pharmaceuticals Appoints Lisa M. Olson as CEO and Announces Clinical Trial Progress with Ent001
Published: 2024-01-23 (Crawled : 12:00) - biospace.com/
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: 0.46%
H: 0.74%
C: -0.04%
ABT | News | $105.27 -0.6% -0.15% 7.3M
|
Health Technology
|
| O: -0.07%
H: 0.0%
C: 0.0%
ceo pharmaceuticals trial
European Commission Approves Pfizer’s TALZENNA® in Combination with XTANDI® for Adult Patients with Metastatic Castration-Resistant Prostate Cancer
Published: 2024-01-08 (Crawled : 18:00) - biospace.com/
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: -0.37%
H: 1.09%
C: 0.75%
talzenna cancer
Pfizer Receives All Required Regulatory Approvals to Complete the Acquisition of Seagen
Published: 2023-12-12 (Crawled : 15:30) - biospace.com/
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: -0.07%
H: 0.84%
C: -0.14%
SGEN | $228.74 0.1% 20M
|
Health Technology
|
| O: 3.27%
H: 0.0%
C: 0.0%
acquisition
European Commission Approves Pfizer’s ELREXFIO® for Relapsed and Refractory Multiple Myeloma
Published: 2023-12-08 (Crawled : 21:00) - biospace.com/
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: 0.07%
H: 1.1%
C: 0.45%
elrexfio
Latest Novartis Kisqali® NATALEE analysis reinforces 25% reduction in risk of recurrence across broad population of patients with early breast cancer; supports regulatory submissions - December 8, 2023
Published: 2023-12-08 (Crawled : 16:00) - biospace.com/
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: -1.29%
H: 0.4%
C: 0.4%
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: 0.07%
H: 1.1%
C: 0.45%
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: 0.19%
H: 0.35%
C: 0.2%
kisqali breast risk novartis
Pfizer Announces Topline Phase 2b Results of Oral GLP-1R Agonist, Danuglipron, in Adults with Obesity
Published: 2023-12-01 (Crawled : 22:00) - biospace.com/
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: -4.92%
H: 1.48%
C: -0.21%
obesity topline results
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference - November 21, 2023
Published: 2023-11-21 (Crawled : 17:00) - biospace.com/
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: 0.13%
H: 1.13%
C: 0.93%
conference
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.